● Recruiting

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Condition: Chronic Lymphocytic Leukemia · Hematopoietic and Lymphoid System Neoplasm · Mantle Cell Lymphoma · Sponsor: Mayo Clinic

PhaseN/A

Planned participants100

Who can joinAll sexes, N/A to no upper limit

Healthy volunteersNo

About this study

This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials Referral Office · 855-776-0015 · mayocliniccancerstudies@mayo.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06151730